Research programme: iPSC-derived cell replacement therapy - GABAeron
Latest Information Update: 10 Feb 2022
At a glance
- Originator GABAeron
- Class Antidementias; Cell therapies
- Mechanism of Action Cell replacements; GABA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 01 Feb 2022 Preclinical trials in Alzheimer's disease in USA (Parenteral) before February 2022 (GABAeron pipeline, February 2022)